Literature DB >> 11302827

In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.

H J Linde1, M Schmidt, E Fuchs, U Reischl, H H Niller, N Lehn.   

Abstract

Of 94 clinical isolates of Staphylococcus aureus (n = 51) and coagulase-negative staphylococci (CNS) (n = 43), mutations in the quinolone resistance-determining region of topoisomerases GrlA, GrlB, GyrA, and GyrB together with MICs of six quinolones were analyzed. Amino acid substitutions at identical residues (GrlA residues 80 and 84; GyrA residues 84 and 88) were found in S. aureus and CNS. Active efflux, as suggested by blocking by reserpine, contributed substantially to the resistance phenotype in some strains. Among ciprofloxacin, clinafloxacin, levofloxacin, nalidixic acid, trovafloxacin, and sparfloxacin, a 0.5-microg/ml concentration of sparfloxacin discriminated best between strains with two or three mutations and those with no mutations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302827      PMCID: PMC90505          DOI: 10.1128/AAC.45.5.1553-1557.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  S Sreedharan; L R Peterson; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

2.  Comparative activities of clinafloxacin against gram-positive and -negative bacteria.

Authors:  L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.

Authors:  F J Schmitz; B Hofmann; B Hansen; S Scheuring; M Lückefahr; M Klootwijk; J Verhoef; A Fluit; H P Heinz; K Köhrer; M E Jones
Journal:  J Antimicrob Chemother       Date:  1998-04       Impact factor: 5.790

4.  Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine.

Authors:  P N Markham
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

5.  Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.

Authors:  D Ince; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.

Authors:  M Tanaka; Y Onodera; Y Uchida; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Cloning and restriction analysis of DNA conferring new quinolone antimicrobial agent resistance from Staphylococcus aureus and other coagulase-negative Staphylococcus species.

Authors:  T Yamamoto; S Takubo; K Fujita; T Oguri; T Yokota
Journal:  FEMS Microbiol Lett       Date:  1990-03-15       Impact factor: 2.742

8.  Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.

Authors:  Z Li; T Deguchi; M Yasuda; T Kawamura; E Kanematsu; Y Nishino; S Ishihara; Y Kawada
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.

Authors:  H Ito; H Yoshida; M Bogaki-Shonai; T Niga; H Hattori; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

View more
  6 in total

1.  Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.

Authors:  Tatiana Bogdanovich; Duygu Esel; Linda M Kelly; Bülent Bozdogan; Kim Credito; Gengrong Lin; Kathy Smith; Lois M Ednie; Dianne B Hoellman; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.

Authors:  Gengrong Lin; Kim Credito; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

3.  Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.

Authors:  Dianne B Hoellman; Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

4.  Prevalence of the Antibiotic Resistance Genes in Coagulase-Positive-and Negative-Staphylococcus in Chicken Meat Retailed to Consumers.

Authors:  Kamelia Osman; Jihan Badr; Khalid S Al-Maary; Ihab M I Moussa; Ashgan M Hessain; Zeinab M S Amin Girah; Usama H Abo-Shama; Ahmed Orabi; Aalaa Saad
Journal:  Front Microbiol       Date:  2016-11-22       Impact factor: 5.640

5.  Prevalence and Genetic Basis of Antimicrobial Resistance in Non-aureus Staphylococci Isolated from Canadian Dairy Herds.

Authors:  Diego B Nobrega; Sohail Naushad; S Ali Naqvi; Larissa A Z Condas; Vineet Saini; John P Kastelic; Christopher Luby; Jeroen De Buck; Herman W Barkema
Journal:  Front Microbiol       Date:  2018-02-16       Impact factor: 5.640

6.  Antimicrobial Resistance, Biofilm Formation and mecA Characterization of Methicillin-Susceptible S. aureus and Non-S. aureus of Beef Meat Origin in Egypt.

Authors:  Kamelia M Osman; Aziza M Amer; Jihan M Badr; Nashwa M Helmy; Rehab A Elhelw; Ahmed Orabi; Magdy Bakry; Aalaa S A Saad
Journal:  Front Microbiol       Date:  2016-02-29       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.